CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Pregabalin 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00977197
NCT00977197Phase 2Completed
CompareCT.gov

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

Mayo Clinic·interventional·Posted Sep 15, 2009·Updated Oct 28, 2016

In Brief

A Phase 2 clinical trial evaluating Pregabalin and Placebo for Irritable Bowel Syndrome. Completed, enrolled 85 participants across 2 sites.

Detailed Summary

This study is being done to see if Lyrica helps people with irritable bowel syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2009
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.8 years ago

Interventions

Pregabalindrug

Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.

Placebodrug

A matching placebo will be administered twice a day